News

An announcement of the top-line results from a European phase 3 clinical trial of TUDCA revealed that the primary endpoint of the study was not met as TUDCA failed to demonstrate an ability to significantly alter the progression of ALS…

Eight projects receive funding to find answers and fuel discoveries in ALS research Toronto – In their effort to fund progress and innovation in amyotrophic lateral sclerosis (ALS) research, the ALS Society of Canada (ALS Canada) and Brain Canada are…

Quebec researcher receives $250,000 over three years to investigate gene-based research to treat ALS Toronto – The ALS Society of Canada (ALS Canada) and Brain Canada are dedicated to a shared mission to advance amyotrophic lateral sclerosis (ALS) research. Together,…

Funding for first two projects to total $200,000 Toronto – Amyotrophic lateral sclerosis (ALS) is a disease that can progress with startling swiftness. The ALS Society of Canada (ALS Canada) recognizes the need to move quickly in funding promising research…

Updated on: January 31, 2024 Pharmaceutical company Ferrer has announced topline results from the ADORE (ALS Deceleration with ORral Edaravone) clinical trial in ALS. The Phase 3 study, conducted in Europe, investigated the efficacy of an oral formulation of edaravone…

A study published today in Muscle & Nerve on the long-term data from the CENTAUR clinical trial and open-label extension shows that AMX0035 has promise for extending survival in people living with ALS. The results demonstrated that early treatment with…

A study published today in the New England Journal of Medicine shows that AMX0035, an experimental therapy, has promise for slowing the progression of ALS. AMX0035 is an oral drug that contains two small molecules, which when combined, aim to…

July 9, 2020 – A study published today in the New England Journal of Medicine shows that an experimental drug, called tofersen, has promise for treating a genetic form of ALS caused by mutations in the gene SOD1. Results from…